This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by PERRY, H. M. Articles by SCHROEDER, H. A. Search for Related Content PubMed PubMed Citation Articles by PERRY, H. M., JR. Articles by SCHROEDER, H. A.

(Circulation. 1956;14:105.)
© 1956 American Heart Association, Inc.

---

Studies on the Control of Hypertension. VII. Effects of Ganglionic Blockade Combined With Hydralazine on the Malignant Stage Complicated by Renal Azotemia

H. MITCHELL PERRY JR. M.D.¹ HENRY A. SCHROEDER M.D.¹

¹ From the Hypertension Division, Department of Internal Medicine, Washington University School of Medicine and Barnes Hospital, Saint Louis, Mo.

The malignant stage of arterial hypertension complicated by azotemia is usually a rapidly fatal disorder. The elevated blood pressures of 82 patients in this stage were chronically lowered by the regular, continued use of oral ganglionic-blocking agents and hydralazine hydrochloride in doses sufficient to control their hypertension without provoking dangerous hypotension or further azotemia. By careful administration of these potent antihypertensive drugs the mortality rate of azotemic patients was significantly reduced. The malignant stage of hypertension that has progressed to moderate renal insufficiency is no longer a rapidly fatal disease when properly treated, while that which has progressed further is usually uninfluenced.